PURPOSE: The aim of this study was to evaluate the feasibility of hybrid [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/MRI in patients with large vessel vasculitis (LVV) by comparing visual and quantitative parameters to that of PET/CT. Furthermore, the value of PET/MRI in disease activity and extent of LVV was assessed. METHODS: A total of 16 [(18)F]FDG PET/MRI and 12 [(18)F]-FDG PET/CT examinations were performed in 12 patients with LVV. MRI of the vessel wall by T1-weighted and T2-weighted sequences was used for anatomical localization of FDG uptake and identification of morphological changes associated with LVV. In addition, contrast-enhanced (CE) magnetic resonance angiography (MRA) was performed. The vascular FDG uptake in the vasculitis group was compared to a reference group of 16 patients using a four-point visual score. Visual scores and quantitative parameters [maximum standardized uptake value (SUVmax) and target to background ratio (TBR)] were compared between PET/MRI and PET/CT. Furthermore, correlations between C-reactive protein (CRP) and quantitative PET results, as well the extent of vasculitis in PET, MRI/CE-MRA and combined PET/MRI, were analysed. RESULTS: TBRs, SUVmax values and visual scores correlated well between PET/MRI and PET/CT (r = 0.92, r = 0.91; r = 0.84, p < 0.05). There was no significant difference between both modalities concerning SUVmax measurements and visual scores. In PET/MRI, PET alone revealed abnormal FDG uptake in 86 vascular regions. MRI/CE-MRA indicated 49 vessel segments with morphological changes related to vasculitis, leading to a total number of 95 vasculitis regions in combination with PET. Strong and significant correlations between CRP and disease extent in PET alone (r = 0.75, p = 0.0067) and PET/MRI (r = 0.92, p < 0.0001) in contrast to MRI/CE-MRA only were observed. Regarding disease activity, no significant correlations were seen between quantitative PET results and CRP, although there was a trend towards significance (r = 0.55, p = 0.0651). PET/MRI also showed active LVV in 15/16 examinations. CONCLUSION: Hybrid PET/MRI is feasible in LVV and holds promise for precisely determining disease extent and disease activity.
PURPOSE: The aim of this study was to evaluate the feasibility of hybrid [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/MRI in patients with large vessel vasculitis (LVV) by comparing visual and quantitative parameters to that of PET/CT. Furthermore, the value of PET/MRI in disease activity and extent of LVV was assessed. METHODS: A total of 16 [(18)F]FDG PET/MRI and 12 [(18)F]-FDG PET/CT examinations were performed in 12 patients with LVV. MRI of the vessel wall by T1-weighted and T2-weighted sequences was used for anatomical localization of FDG uptake and identification of morphological changes associated with LVV. In addition, contrast-enhanced (CE) magnetic resonance angiography (MRA) was performed. The vascular FDG uptake in the vasculitis group was compared to a reference group of 16 patients using a four-point visual score. Visual scores and quantitative parameters [maximum standardized uptake value (SUVmax) and target to background ratio (TBR)] were compared between PET/MRI and PET/CT. Furthermore, correlations between C-reactive protein (CRP) and quantitative PET results, as well the extent of vasculitis in PET, MRI/CE-MRA and combined PET/MRI, were analysed. RESULTS:TBRs, SUVmax values and visual scores correlated well between PET/MRI and PET/CT (r = 0.92, r = 0.91; r = 0.84, p < 0.05). There was no significant difference between both modalities concerning SUVmax measurements and visual scores. In PET/MRI, PET alone revealed abnormal FDG uptake in 86 vascular regions. MRI/CE-MRA indicated 49 vessel segments with morphological changes related to vasculitis, leading to a total number of 95 vasculitis regions in combination with PET. Strong and significant correlations between CRP and disease extent in PET alone (r = 0.75, p = 0.0067) and PET/MRI (r = 0.92, p < 0.0001) in contrast to MRI/CE-MRA only were observed. Regarding disease activity, no significant correlations were seen between quantitative PET results and CRP, although there was a trend towards significance (r = 0.55, p = 0.0651). PET/MRI also showed active LVV in 15/16 examinations. CONCLUSION: Hybrid PET/MRI is feasible in LVV and holds promise for precisely determining disease extent and disease activity.
Authors: J Meller; F Strutz; U Siefker; A Scheel; C O Sahlmann; K Lehmann; M Conrad; R Vosshenrich Journal: Eur J Nucl Med Mol Imaging Date: 2003-04-04 Impact factor: 9.236
Authors: J Andrews; A Al-Nahhas; D J Pennell; M S Hossain; K A Davies; D O Haskard; J C Mason Journal: Ann Rheum Dis Date: 2004-08 Impact factor: 19.103
Authors: Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-10 Impact factor: 9.236
Authors: Gaspar Delso; Sebastian Fürst; Björn Jakoby; Ralf Ladebeck; Carl Ganter; Stephan G Nekolla; Markus Schwaiger; Sibylle I Ziegler Journal: J Nucl Med Date: 2011-11-11 Impact factor: 10.057
Authors: Martin A Walter; Ralph A Melzer; Christian Schindler; Jan Müller-Brand; Alan Tyndall; Egbert U Nitzsche Journal: Eur J Nucl Med Mol Imaging Date: 2005-03-04 Impact factor: 9.236
Authors: G S Kerr; C W Hallahan; J Giordano; R Y Leavitt; A S Fauci; M Rottem; G S Hoffman Journal: Ann Intern Med Date: 1994-06-01 Impact factor: 25.391
Authors: J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg Journal: Circulation Date: 2002-06-11 Impact factor: 29.690
Authors: Elena Incerti; Enrico Tombetti; Federico Fallanca; Elena M Baldissera; Pierpaolo Alongi; Elisabetta Tombolini; Silvia Sartorelli; Maria Grazia Sabbadini; Maurizio Papa; Francesco De Cobelli; Justin C Mason; Luigi Gianolli; Angelo A Manfredi; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-08 Impact factor: 9.236
Authors: Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta Journal: Nat Rev Rheumatol Date: 2017-09-14 Impact factor: 20.543
Authors: Kaitlin A Quinn; Mark A Ahlman; Ashkan A Malayeri; Jamie Marko; Ali Cahid Civelek; Joel S Rosenblum; Armin A Bagheri; Peter A Merkel; Elaine Novakovich; Peter C Grayson Journal: Ann Rheum Dis Date: 2018-04-17 Impact factor: 19.103
Authors: Charlotte L Harrington; Amit K Dey; Raza Yunus; Aditya A Joshi; Nehal N Mehta Journal: Am J Physiol Heart Circ Physiol Date: 2017-03-03 Impact factor: 4.733
Authors: Kaitlin A Quinn; Joel S Rosenblum; Casey A Rimland; K Bates Gribbons; Mark A Ahlman; Peter C Grayson Journal: Semin Arthritis Rheum Date: 2019-07-24 Impact factor: 5.532
Authors: Kam A Newman; Mark A Ahlman; Marybeth Hughes; Ashkan A Malayeri; Drew Pratt; Peter C Grayson Journal: Arthritis Rheumatol Date: 2016-05 Impact factor: 10.995